Tidalsense raised $19 million to scale N-Tidal Diagnose, its AI-powered platform for identifying chronic obstructive pulmonary disease (COPD) in about five minutes. The funding round is positioned around near-term deployment of rapid diagnostic workflows that could reduce delays from symptom onset to clinical decision-making. The company’s approach targets faster COPD recognition than traditional care pathways, which often require clinician interpretation and longer testing timelines. For payers and providers, the proposition centers on shortening the window between suspect diagnosis and treatment planning. The financing highlights ongoing investor appetite for diagnostic tools that can translate AI into clinic-ready turnaround times rather than research-only proof of concept.